Profile banner
Zavain Dar

Zavain Dar

Investor, Founder, and Computer Scientist at the intersection of tech and life sciences

New York, New York
Joined August 2025

Network

12.8K connections
πŸ’°
Deep Tech Investors
🧬
Biotech Founders CEOs
🏦
Endowment Institutional Investors
πŸ€–
AI ML Researchers
🌐
Recursion Network
🌱
Enveda
πŸ’‘
Dimension Leadership Research

Summary

Zavain Dar is a prominent venture capitalist and founder with a deep focus on the convergence of cutting-edge technology, particularly AI and machine learning, with life sciences. He co-founded Dimension Capital to invest in this space and previously served as a General Partner at Lux Capital, where he led numerous investments in pioneering biotech and software companies. dimensioncap+3
His expertise extends beyond investment into company building, scientific research, and engineering, reflecting a hands-on approach to fostering innovation. He holds board directorships at significant biotech firms like Recursion Pharmaceuticals and Enveda Biosciences, demonstrating his commitment to guiding companies that leverage technology for scientific advancements and new medicine discovery. dimensioncap+2
Academically, Dar has a strong computer science background from Stanford University, where he earned both a BS in Symbolic Systems and an MS in Computer Science, conducting research at the Stanford AI Lab. He also shared his knowledge as a lecturer at Stanford, teaching seminars on cutting-edge topics including cryptocurrencies, AI and philosophy, and venture capital. oreilly+2
Prior to his venture capital career, Dar was a founder and computer scientist, co-founding Fountainhop, one of the early hyperlocal social networks, and serving as a Ranking Engineer at Discovery Engine (acquired by Twitter), where he developed machine learning and AI systems for web-scale ranking algorithms. This experience underpins his deep technical understanding and entrepreneurial drive. recursion+1

Work

Education

Notes

SHsriram hathwarsaid that if they were starting a groundbreaking biotech company,
ZDZavain Dar
would be among their first picks for an early backer.

Dec 2, 2025